InMed (INM) sets 2025 annual & special meeting; SEDAR update

Q: When was the announcement made?

The announcement was made on October 10, 2025.

Q: Where can shareholders find the detailed meeting information?

Details are in a revised filing submitted to SEDAR and attached as Exhibit 99.1.

Q: What is the form type of this disclosure?

It is a Form 8-K under Item 8.01 (Other Events).

Q: What securities are listed for InMed (INM)?

InMed’s common shares trade on The Nasdaq Stock Market LLC under the symbol INM.

Q: Who signed the report for InMed?

The report was signed by Eric A. Adams, President and CEO.

InMed Pharmaceuticals (INM) reported an administrative update.

Accepted by SEC EDGAR 10/10/2025 - 07:50 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

InMed Pharmaceuticals (INM) reported an administrative update. On October 10, 2025, the company announced the meeting, record date, and related details for its 2025 annual general and special meeting of shareholders, as reflected in a revised submission to Canada’s SEDAR system. The notice was furnished via an 8-K under Item 8.01, with the SEDAR filing listed as Exhibit 99.1.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did InMed (INM) announce in this 8-K?

InMed announced the meeting, record date, and related details for its 2025 annual general and special meeting of shareholders, referencing a revised SEDAR filing.

When was the announcement made?

The announcement was made on October 10, 2025.

Where can shareholders find the detailed meeting information?

Details are in a revised filing submitted to SEDAR and attached as Exhibit 99.1.

What is the form type of this disclosure?

It is a Form 8-K under Item 8.01 (Other Events).

What securities are listed for InMed (INM)?

InMed’s common shares trade on The Nasdaq Stock Market LLC under the symbol INM.

Who signed the report for InMed?

The report was signed by Eric A. Adams, President and CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 10, 2025

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

InMed Pharmaceuticals Inc. Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada		V6C 3E8
(Address of Principal Executive Offices)		(Zip Code)

Company’s telephone number, including area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On October 10, 2025, InMed Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2025 annual general and special meeting of shareholders pursuant to a revised filing submitted to the System for Electronic Document Analysis and Retrieval (“SEDAR”) in Canada.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.		Description
99.1		SEDAR filing submitted October 10, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMED PHARMACEUTICALS INC.

Date: October 10, 2025	By:	/s/ Eric A. Adams
		Eric A. Adams
		President and CEO

Source: View Original Filing on SEC EDGAR